Colorectal Cancer Clinical Trials in Omaha, Nebraska

6 studies are recruiting for colorectal cancer in Omaha, Nebraska right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    University of Nebraska Medical Center Buffet Cancer Center, Omaha, Nebraska
    Locations
    77 in total
    Run by
    PMV Pharmaceuticals, Inc
  2. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Nebraska Cancer Specialists, Omaha, Nebraska
    Locations
    32 in total
    Run by
    Revolution Medicines, Inc.
  3. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

    Stage
    Phase 1
    Ages
    18 to 90
    Site
    Nebraska Cancer Specialists, Omaha, Nebraska
    Locations
    11 in total
    Run by
    Perspective Therapeutics
  4. 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

    A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Nebraska Cancer Specialists, Omaha, Nebraska
    Locations
    4 in total
    Run by
    Radiopharm Theranostics, Ltd
  5. A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans

    African Americans face racial disparities in colorectal cancer (CRC), with lower screening rates and higher incidence and mortality rates. To address this gap and improve CRC screening rates, investigators aims to recruit a total of 1,200 African American participants aged 45-75 during their visits…

    Stage
    Not phased
    Ages
    45 to 75
    Site
    Department of Motor Vehicles (DMV), Omaha, Nebraska
    Locations
    2 in total
    Run by
    University of Nebraska
  6. Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

    The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Nebraska Cancer Specialists, Omaha, Nebraska
    Locations
    20 in total
    Run by
    Tempus AI

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.